How to appeal a Cigna pediatric epilepsy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for pediatric epilepsy

Cited policy: Cigna H.P. Acthar Gel (Repository Corticotropin) for Infantile Spasms

Infantile epileptic spasms syndrome (IESS / West syndrome) diagnosis — clinical spasms + hypsarrhythmia or modified hypsarrhythmia on EEG (video-EEG documentation required). Age 2 mo - 24 mo. Standard regimen 150 U/m^2/day IM divided BID x 2 wk + taper. Inpatient or close outpatient monitoring (HTN, hyperglycemia, immunosuppression, irritability). Reauth not typical — single course unless relapse.

How Cigna denies pediatric epilepsy — and how to counter it

Where Cigna pushes back: 1) Try prednisolone first (cheaper, ~$50 vs ~$30,000); 2) Try vigabatrin first; 3) Acthar not preferred over synthetic ACTH analog (synthetic unavailable in US).

Counter-arguments that hold up: AES 2010 update Go Neurology 2012 + AES 2024 update Wirrell — ACTH first-line for non-TSC infantile spasms. UKISS Lux Lancet 2004 — hormonal therapy superior to vigabatrin for spasm cessation in non-TSC IS (73% vs 54%). ICISS O'Callaghan Lancet Neurol 2017 — combination ACTH+vigabatrin further superior to either alone. Time-to-cessation matters — every week of ongoing hypsarrhythmia worsens neurodevelopmental outcome (Riikonen Brain Dev 2010). Cost should not delay first-line therapy — neurodevelopmental sequelae are lifelong. For TSC IS specifically, vigabatrin is preferred per AES 2024 + EPISTOP NEJM 2021 Kotulska.

What Cigna typically denies for pediatric epilepsy

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric epilepsy, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the pediatric epilepsy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Epidiolex
• Fintepla
• Diacomit
• Clobazam (Onfi/Sympazan)
• Banzel
• Ztalmy (CDKL5)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.